Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased bone resorption. Subcutaneous denosumab administ...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academya Publishing Co.
2015-03-01
|
| Series: | Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-30-19.pdf |